Asthma Does Not Seem to Increase the Severity of COVID-19
Asthma does not appear to increase the risk for a person contracting COVID-19 or influence its severity, according to a team of Rutgers researchers.
Read moreInflammation
Cancer Researchers Have a Head Start in Fight Against COVID-19
Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.
Read more
Immune from Chronic Stress? Limit Inflammatory Signaling to Specific Brain Circuits
Chronic stress is associated with the pathogenesis of psychological disorders such as depression. A study is the first to identify the role of a neuronal receptor that straddles the intersection between social stress, inflammation, and anxiety in rodent models of stress. Findings suggest the possibility of developing better medications to treat the consequences of chronic stress by limiting inflammatory signaling not just generally, which may not be beneficial in the long run, but to specific brain circuits.
Read more
Cognitive behavior therapy tops other psychotherapies in reducing inflammation
A review of 56 randomized clinical trials finds that psychological and behavioral therapies may be effective non-drug treatments for reducing disease-causing inflammation in the body.
Read moreA satisfying romantic relationship may improve breast cancer survivors’ health
Breast cancer survivors in romantic relationships who feel happy and satisfied with their partners may be at lower risk for a host of health problems, new research suggests.
Read more
Exposure to ‘good bacteria’ during pregnancy buffers risk of autism-like syndrome in offspring
Inoculation with a beneficial microorganism during pregnancy fended off an autism-like syndrome in offspring, according to a new animal study. The paper is the latest to suggest that ‘good bacteria’ impacts the brain.
Read moreMontefiore and Einstein Test a New Drug Combination to Conquer COVID-19
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Read moreChildren Not Immune to Coronavirus; New Study from Pandemic Epicenter Describes Severe COVID-19 Response in Children
While most children infected with the novel coronavirus have mild symptoms, a subset requires hospitalization and a small number require intensive care. A new report from pediatric anesthesiologists, infectious disease specialists and pediatricians at the Children’s Hospital at Montefiore (CHAM) and Albert Einstein College of Medicine, describes the clinical characteristics and outcomes of children hospitalized with COVID-19, during the early days of the pandemic.
Read more
Higher Levels of NETs in Blood Associated with More Severe COVID-19
New study explores the connection between levels of a type of destructive white blood cell, known as a neutrophil, with the severity of COVID-19.
Read moreScientists receive NIH grant to support study using THC as therapy for HIV patients suffering from inflammation
More than $3.7 million was awarded to Mahesh Mohan, DVM, MS, Ph.D., Professor at the Texas Biomedical Research Institute, and Chioma M. Okeoma, Ph.D., Associate Professor at Stony Brook University, to explore the link between cannabinoids (THC) and chronic intestinal inflammation in patients infected with the human immunodeficiency virus (HIV).
Read more